IRIS
BERSANELLI, MELISSA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 3.131
AS - Asia 3.001
EU - Europa 2.065
SA - Sud America 738
AF - Africa 218
Continente sconosciuto - Info sul continente non disponibili 2
OC - Oceania 2
Totale 9.157
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.037
SG - Singapore 1.503
BR - Brasile 596
IE - Irlanda 586
CN - Cina 579
SE - Svezia 453
HK - Hong Kong 342
VN - Vietnam 272
IT - Italia 225
DE - Germania 166
ZA - Sudafrica 155
NL - Olanda 146
AT - Austria 115
FI - Finlandia 81
FR - Francia 70
RU - Federazione Russa 58
AR - Argentina 52
GB - Regno Unito 48
IR - Iran 46
CA - Canada 42
IN - India 37
BD - Bangladesh 36
ID - Indonesia 32
MX - Messico 32
EC - Ecuador 30
TR - Turchia 26
IQ - Iraq 25
BE - Belgio 22
CZ - Repubblica Ceca 18
CO - Colombia 17
PL - Polonia 17
JP - Giappone 15
CI - Costa d'Avorio 13
MA - Marocco 13
LT - Lituania 11
UA - Ucraina 11
PY - Paraguay 10
VE - Venezuela 10
EG - Egitto 9
KR - Corea 9
UZ - Uzbekistan 9
AE - Emirati Arabi Uniti 8
ES - Italia 8
KZ - Kazakistan 8
CL - Cile 7
KE - Kenya 7
NP - Nepal 7
PK - Pakistan 7
DO - Repubblica Dominicana 6
EE - Estonia 6
PE - Perù 6
BG - Bulgaria 5
BO - Bolivia 5
SA - Arabia Saudita 5
UY - Uruguay 5
DZ - Algeria 4
OM - Oman 4
PA - Panama 4
SN - Senegal 4
AL - Albania 3
AZ - Azerbaigian 3
BH - Bahrain 3
CR - Costa Rica 3
KG - Kirghizistan 3
KW - Kuwait 3
TN - Tunisia 3
AO - Angola 2
AU - Australia 2
CH - Svizzera 2
GT - Guatemala 2
HN - Honduras 2
HU - Ungheria 2
IL - Israele 2
JO - Giordania 2
MY - Malesia 2
NG - Nigeria 2
PS - Palestinian Territory 2
RO - Romania 2
TW - Taiwan 2
BN - Brunei Darussalam 1
BS - Bahamas 1
BY - Bielorussia 1
CV - Capo Verde 1
CY - Cipro 1
ET - Etiopia 1
EU - Europa 1
GA - Gabon 1
GE - Georgia 1
GM - Gambi 1
HR - Croazia 1
JM - Giamaica 1
KH - Cambogia 1
LB - Libano 1
LU - Lussemburgo 1
MD - Moldavia 1
ME - Montenegro 1
MK - Macedonia 1
NO - Norvegia 1
PH - Filippine 1
QA - Qatar 1
Totale 9.148
Salva come PNG Salva come JPEG
Città #
Singapore 706
Dublin 580
Ashburn 491
Chandler 462
Hong Kong 341
Santa Clara 315
Boardman 179
Dallas 162
Beijing 159
Johannesburg 142
Princeton 113
Vienna 109
Ho Chi Minh City 104
Shanghai 101
Ann Arbor 79
Munich 69
Hanoi 67
Los Angeles 65
New York 65
São Paulo 57
Helsinki 55
Tehran 38
Parma 31
Columbus 30
Moscow 30
Rio de Janeiro 29
Bremen 28
Wilmington 26
Milan 25
Turku 25
Des Moines 24
The Dalles 24
Jakarta 23
Chicago 22
Brussels 21
Frankfurt am Main 21
Nuremberg 21
Buffalo 19
Council Bluffs 18
Guayaquil 16
Belo Horizonte 15
Bologna 15
Stockholm 15
Brasília 14
Hefei 14
London 14
Phoenix 14
Seattle 14
Tianjin 14
Warsaw 14
Abidjan 13
Boston 13
Dearborn 12
Orem 12
Toronto 12
Baghdad 11
Brooklyn 11
Chennai 11
Curitiba 11
Haiphong 11
Montreal 11
Rome 11
Atlanta 10
Düsseldorf 10
Guangzhou 10
Houston 10
Marseille 10
Nanjing 10
Brno 9
Denver 9
Quito 9
Tashkent 9
Ankara 8
Hải Dương 8
Lauterbourg 8
Poplar 8
Tokyo 8
Verona 8
Biên Hòa 7
Borås 7
Fortaleza 7
Fremont 7
Olomouc 7
Rio Saliceto 7
San Francisco 7
Seoul 7
Sorocaba 7
Bauru 6
Buenos Aires 6
Bắc Ninh 6
Da Nang 6
Dhaka 6
Dong Ket 6
Fairfield 6
Jinan 6
Modena 6
Nairobi 6
San Mateo 6
St Petersburg 6
Vancouver 6
Totale 5.459
Salva come PNG Salva come JPEG
Nome #
Correlations between tumor-infiltrating and circulating lymphocyte subpopulations in advanced renal cancer patients treated with nivolumab 174
The Prognostic Role of High Blood Cholesterol in Advanced Cancer Patients Treated With Immune Checkpoint Inhibitors 163
PREDICTIVE AND PROGNOSTIC VALUE OF CLINICAL AND MOLECULAR FEATURES IN PATIENTS UNDERGOING PULMONARY METASTASECTOMY FROM RENAL CELL CARCINOMA 152
The Urinary Microbiome and Anticancer Immunotherapy: The Potentially Hidden Role of Unculturable Microbes 136
The role of blood cholesterol quality in patients with advanced cancer receiving immune checkpoint inhibitors 129
Review on radiological evolution of COVID-19 pneumonia using computed tomography 129
1929O Soluble PD-L1 and circulating CD8+PD1+ and NK cells enclose a highly prognostic and predictive immune effector score in immunotherapy treated NSCLC patients 127
Immune context characterization and heterogeneity in primary tumors and pulmonary metastases from renal cell carcinoma 125
Soluble PD-L1 and Circulating CD8+PD-1+ and NK Cells Enclose a Prognostic and Predictive Immune Effector Score in Immunotherapy Treated NSCLC patients 123
Another side of the association between body mass index (BMI) and clinical outcomes of cancer patients receiving programmed cell death protein-1 (PD-1)/ Programmed cell death-ligand 1 (PD-L1) checkpoint inhibitors: A multicentre analysis of immune-related adverse events 120
Circulating immune-profile as predictor of outcome in advanced NSCLC patients treated with Nivolumab 120
Antibiotic-dependent effect of probiotics in patients with non-small cell lung cancer treated with PD-1 checkpoint blockade 118
Asymptomatic pulmonary embolism in lung cancer: Prevalence and analysis of clinical and radiological characteristics in 141 outpatients 118
Author Correction: Validation of the GRade, Age, Nodes and Tumor (GRANT) score within the Surveillance Epidemiology and End Results (SEER) database: A new tool to predict survival in surgically treated renal cell carcinoma patients (Scientific Reports, (2019), 9, 1, (13218), 10.1038/s41598-019-49250-6) 114
Retrospective immunophenotypical evaluation of MET, PD-1/PD-L1, and mTOR pathways in primary tumors and pulmonary metastases of renal cell carcinoma: the RIVELATOR study addresses the issue of biomarkers heterogeneity 113
INfluenza Vaccine Indication during therapy with Immune checkpoint inhibitors: A multicenter prospective observational study (INVIDIa-2) 113
Anaplastic lymphoma kinase as a new target for the treatment of non-small-cell lung cancer 111
Prognostic value of 18F-FDG standard uptake value by integrated PET/CT in the staging of malignant pleural mesothelioma 107
Clinical Impact of COVID-19 Outbreak on Cancer Patients: A Retrospective Study 105
Clinical and hematologic parameters address the outcomes of non-small-cell lung cancer patients treated with nivolumab 102
Palliative radiotherapy in advanced cancer patients treated with immune-checkpoint inhibitors: The practice study 102
PD-L1 SNPs as biomarkers to define benefit in patients with advanced NSCLC treated with immune checkpoint inhibitors 101
Differential diagnosis of COVID-19 at the chest computed tomography scan: A review with special focus on cancer patients 100
Clinical impact of COVID-19 in a single-center cohort of a prospective study in cancer patients receiving immunotherapy 99
Cabozantinib in metastatic renal cell carcinoma: Latest findings and clinical potential 97
BOLERO-3 results: Pharmacological activity or pharmacokinetic effect? 95
Antiangiogenic tyrosine kinase inhibitors and immunotherapy as first-line treatment for metastatic renal cell carcinoma: is there an increased risk of hypothyroidism? 95
Validation of a Novel Three-Dimensional (3D Fusion) Gross Sampling Protocol for Clear Cell Renal Cell Carcinoma to Overcome Intratumoral Heterogeneity: The Meet-Uro 18 Study 95
Gefitinib plus interleukin-2 in advanced non-small cell lung cancer patients previously treated with chemotherapy 93
The right immune-modulation at the right time: thymosin α1 for prevention of severe COVID-19 in cancer patients 92
Chemotherapy in non-small cell lung cancer patients after prior immunotherapy: The multicenter retrospective CLARITY study 90
Avelumab Maintenance for Urothelial Carcinoma 90
1462P Clinical outcome of patients with non-clear metastatic renal cell carcinoma treated with pembrolizumab-axitinib combination: NEMESIA (non-clear metastatic renal cell carcinoma pembrolizumab axitinib) study, a subgroup analysis of I-RARE observational study (Meet-URO 23a) 88
Immunological insights on influenza infection and vaccination during immune checkpoint blockade in cancer patients 88
The effect of COVID-19 emergency in the management of melanoma in Italy 88
Treatment Outcome of metastatic lesions from renal cell carcinoma underGoing Extra-cranial stereotactic body radioTHERapy: The together retrospective study 88
Retroperitoneal cystoadenocarcinoma: A case report with a literature review 86
Cabozantinib in the elderly with metastatic renal cell carcinoma undergoing geriatric G8 screening test: A prospective multicenter observational study (ZEBRA/MEET-URO 9) 84
A metanalysis on cabozantinib and bone metastases: True story or commercial gimmick? 84
Symptomatic COVID-19 in advanced-cancer patients treated with immune-checkpoint inhibitors: prospective analysis from a multicentre observational trial by FICOG 81
Cabozantinib in RCC: only a METEOR or a rising star? 81
Everolimus in the management of metastatic renal cell carcinoma: An evidence-based review of its place in therapy 80
Immunotherapy and Sonpavde score validation in advanced upper tract urothelial carcinoma: a retrospective study by the Italian Network for Research in Urologic-Oncology 80
Correlations Between the Immune-related Adverse Events Spectrum and Efficacy of Anti-PD1 Immunotherapy in NSCLC Patients 79
A multicenter study of body mass index in cancer patients treated with anti-PD-1/PD-L1 immune checkpoint inhibitors: When overweight becomes favorable 78
Feasibility, Safety, and Efficacy of an Alternative Schedule of Sunitinib for the Treatment of Patients with Metastatic Renal Cell Carcinoma: A Retrospective Study 78
Correction to: Feasibility, Safety, and Efficacy of an Alternative Schedule of Sunitinib for the Treatment of Patients with Metastatic Renal Cell Carcinoma: A Retrospective Study (Drugs in R&D, (2017), 17, 4, (585-596), 10.1007/s40268-017-0209-5) 78
Autophagic gene polymorphisms in liquid biopsies and outcome of patients with metastatic clear cell renal cell carcinoma 78
Renal cell carcinoma and viral infections: A dangerous relationship? 77
Outcome and Safety of Sorafenib in Metastatic Renal Cell Carcinoma Dialysis Patients: A Systematic Review 76
Benefit of adjuvant immunotherapy in renal cell carcinoma: A myth or a reality? 76
Patient performance status and cancer immunotherapy efficacy: a meta-analysis 75
Effect of systemic therapies or best supportive care after disease progression to both nivolumab and cabozantinib in metastatic renal cell carcinoma: The Meet‐Uro 19BEYOND study 75
Chemotherapy in metastatic renal cell carcinoma today? A systematic review 73
Predictive ability of a drug-based score in patients with advanced non–small-cell lung cancer receiving first-line immunotherapy 72
First-line pazopanib in patients with advanced non-clear cell renal carcinoma: An Italian case series 72
Effect of concomitant medications with immune-modulatory properties on the outcomes of patients with advanced cancer treated with immune checkpoint inhibitors: development and validation of a novel prognostic index 71
The 'nivolution' in renal cell carcinoma: Behind the scenes of clinical trials 71
Clinical Outcomes of Patients with Advanced Cancer and Pre-Existing Autoimmune Diseases Treated with Anti-Programmed Death-1 Immunotherapy: A Real-World Transverse Study 70
Clinical Outcomes and Toxic Effects of Single-Agent Immune Checkpoint Inhibitors among Patients Aged 80 Years or Older with Cancer: A Multicenter International Cohort Study 70
Primary Retroperitoneal Cystoadenocarcinoma: A Systematic Review 69
Systematic vitamin D supplementation is associated with improved outcomes and reduced thyroid adverse events in patients with cancer treated with immune checkpoint inhibitors: results from the prospective PROVIDENCE study 68
GU-CA-COVID: a clinical audit among Italian genitourinary oncologists during the first COVID-19 outbreak 68
Real World Analysis of Peritoneal Metastasis From Renal Cell Carcinoma. Meet-Uro27 68
A systematic review on the emerging association between the occurrence of immune-related adverse events and clinical outcomes with checkpoint inhibitors in advanced cancer patients 67
A systematic review and meta-analysis on the Optimal Treatment duration of cHEckpoint inhibitoRS in solid tumors: the OTHERS study 66
Capter 4 - Adjuvant Therapy for Renal Cell Carcinoma 65
Spotlight on cabozantinib for previously untreated advanced renal cell carcinoma: Evidence to date 65
The outcome to axitinib or everolimus after sunitinib in metastatic renal cell carcinoma 64
Prognostic significance of host immune status in patients with late relapsing renal cell carcinoma treated with targeted therapy 63
Assessing the effectiveness and safety of lenvatinib and everolimus in advanced renal cell carcinoma: insights from the RELIEVE study’s analysis of heavily pretreated patients 62
Gefitinib and afatinib treatment in an advanced non-small cell lung cancer (NSCLC) patient undergoing hemodialysis 62
Immunotherapy-based combinations versus standard first-line treatment for metastatic clear cell renal cell carcinoma: a systematic review and meta-analysis 62
Cytoreductive nephrectomy in the era of targeted- And immuno- therapy for metastatic renal cell carcinoma: An elusive issue? A systematic review of the literature 61
“Finding NEMO” in NRAS-mutant melanoma: a step towards a sequential strategy? 61
Corrigendum: Validation of a new prognostic model to easily predict outcome in renal cell carcinoma: The GRANT score applied to the ASSURE trial population [Ann Oncol., 28, (2017) (2747-2753)] DOI: 10.1093/annonc/mdx492 60
Reassessing Human Adipose Tissue 59
Pathological nodal staging score for renal cell carcinoma: How to build reliable therapeutic choices basing on assumptions 58
Evaluating the role of FAMIly history of cancer and diagnosis of multiple neoplasms in cancer patients receiving PD-1/PD-L1 checkpoint inhibitors: the multicenter FAMI-L1 study 57
Impact of influenza syndrome and flu vaccine on survival of cancer patients during immunotherapy in the INVIDIa study 57
Clinical outcomes of NSCLC patients experiencing early immune-related adverse events to PD-1/PD-L1 checkpoint inhibitors leading to treatment discontinuation 57
Pazopanib as a possible option for the treatment of metastatic non-clear cell renal carcinoma patients: a systematic review 56
Can we identify a preferred first-line strategy for sarcomatoid renal cell carcinoma? A network meta-analysis 56
Clinical use of lenvatinib in combination with everolimus for the treatment of advanced renal cell carcinoma 55
Metastatic Renal Cell Carcinoma Rapidly Progressive to Sunitinib: What to Do Next? 55
Outcome of patients with advanced upper tract urothelial carcinoma treated with immune checkpoint inhibitors: A systematic review and meta-analysis 54
PD-1/PD-L1 checkpoint inhibitors during late stages of life: an ad-hoc analysis from a large multicenter cohort 54
Family history of cancer as surrogate predictor for immunotherapy with anti-PD1/PD-L1 agents: Preliminary report of the FAMI-L1 study 53
Immune checkpoint inhibitors in adjuvant setting after radical resection of melanoma: a meta-analysis of the pivotal trials 53
Validation of the GRade, Age, Nodes and Tumor (GRANT) score within the Surveillance Epidemiology and End Results (SEER) database: A new tool to predict survival in surgically treated renal cell carcinoma patients 53
Discontinuation of anti-PD1 in advanced melanoma: an observational retrospective study from the Italian Melanoma Intergroup 53
Pazopanib in renal cell carcinoma dialysis patients: A mini-review and a case report 52
INfluenza Vaccine Indication during therapy with Immune checkpoint inhibitors: A transversal challenge. the INVIDIa study 52
Inflammatory indices and clinical factors in metastatic renal cell carcinoma patients treated with nivolumab: the development of a novel prognostic score (Meet-URO 15 study) 52
Role of Bone Metastases in Patients Receiving Immunotherapy for Pre-Treated Urothelial Carcinoma: The Multicentre, Retrospective Meet-URO-1 Bone Study 52
Plasma genotyping for EGFR T790M in non-small cell lung cancer: Ready for clinical practice? 50
From targeting the tumor to targeting the immune system: Transversal challenges in oncology with the inhibition of the PD-1/PD-L1 axis 50
Risk of recurrent venous thromboembolism and major hemorrhage in cancer-associated incidental pulmonary embolism among treated and untreated patients: A pooled analysis of 926 patients 48
State of the art about influenza vaccination for advanced cancer patients receiving immune checkpoint inhibitors: When common sense is not enough 47
Risk of fatigue in cancer patients treated with anti programmed cell death-1/anti programmed cell death ligand-1 agents: A systematic review and meta-analysis 45
Totale 8.154
Salva come PNG Salva come JPEG
Categoria #
all - tutte 43.377
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 43.377
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021114 0 0 0 0 0 23 9 13 22 19 10 18
2021/2022541 11 14 13 24 6 3 160 45 28 6 40 191
2022/20231.984 239 222 118 123 146 224 12 99 691 13 71 26
2023/2024743 39 64 21 20 61 152 52 45 32 44 86 127
2024/20252.642 38 154 195 111 226 351 128 120 263 346 199 511
2025/20263.103 472 476 638 601 846 70 0 0 0 0 0 0
Totale 9.362